Preparation of risperidone
DCFirst Claim
Patent Images
1. A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by x-ray powder diffraction peaks at 14.0±
- 0.2 and 21.7±
0.2 degrees two-theta.
0 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention is directed to the novel forms of risperidone, designated Form A, Form B and Form E. Methods for their preparation are also disclosed. The present invention also relates to processes for making risperidone. Pharmaceutical compositions containing the new forms of risperidone and methods of using them are also disclosed.
4 Citations
22 Claims
-
1. A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by x-ray powder diffraction peaks at 14.0±
- 0.2 and 21.7±
0.2 degrees two-theta. - View Dependent Claims (2, 4, 5, 6, 7, 8)
- 0.2 and 21.7±
-
3. A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by a x-ray powder diffraction pattern substantially as depicted in
FIG. 2 .
-
9. A solid or solid-containing pharmaceutical dosage formulation comprising an active ingredient and at least one component selected from the group consisting of pharmaceutical acceptable carriers and pharmaceutical acceptable excipients, wherein the active ingredient consists essentially of a crystalline form of risperidone characterized by x-ray powder diffraction peaks at 14.0±
- 0.2 and 21.7±
0.2 degrees two-theta. - View Dependent Claims (10, 11)
- 0.2 and 21.7±
-
12. A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by x-ray powder diffraction peaks at 14.0±
- 0.2 and 21.3±
0.2 degrees two-theta. - View Dependent Claims (13, 15, 16, 17, 18, 19)
- 0.2 and 21.3±
-
14. A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by a x-ray powder diffraction pattern sub stantially as depicted in
FIG. 1 .
-
20. A solid or solid-containing pharmaceutical dosage formulation comprising an active ingredient and at least one component selected from the group consisting of pharmaceutical acceptable carriers and pharmaceutical acceptable excipients, wherein the active ingredient consists essentially of a crystalline form of risperidone characterized by x-ray powder diffraction peaks at 14.0±
- 0.2 and 21.3±
0.2 degrees two-theta. - View Dependent Claims (21, 22)
- 0.2 and 21.3±
Specification